A one-stop-shop CRO bringing together innovative platforms, strategic solutions and specialized expertise to drive drug development and advance diverse fields of research.
Policies, Terms & Conditions
10.21.24
Huningue, France – Firalis Molecular Precision (FMP), a CAP-accredited fast-growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announces the winner of its highly competitive Spatial Omics Grant Program —Vincent Anquetil, PhD, Director of Translational Data Science at Alentis Therapeutics. Vincent will receive support from Firalis Molecular Precision to further his research on a novel approach to cancer treatment using spatial omics technology.
Vincent Anquetil’s project, titled “Spatial Insights into T-cell excluded tumors: How ECM remodeling Monoclonal Antibodies can improve immune infiltration”, focuses on the development and molecular characterization of ALE.C04, a monoclonal antibody designed to selectively target Claudin-1 (CLDN1), a protein overexpressed and exposed on the surface of tumor cells. ALE.C04 is currently being evaluated in a Phase 1/2 clinical trial for the treatment of head and neck cancer.
As part of this project, Vincent and his team will leverage Firalis Molecular Precision’s in-house Vizgen spatial omics technology and FMP’s team’s expertise to investigate the molecular impact of ALE.C04 treatment. The study aims to characterize how ALE.C04 alone and in combination with T-cell engagers antibodies (TmAbs) influences intratumoral architecture and immune cell distribution in a pre-clinical tumor model.
The findings from this study have the potential to enhance the efficacy of immunotherapies for cancer, which remains one of the greatest challenges in oncology.
About Vincent Anquetil
Vincent Anquetil joined Alentis Therapeutics in 2022 as Director of Translational Data Science. With over 15 years of experience in OMICs data analysis and translational science, Vincent has become a key player in integrating multimodal data and statistical modeling to advance therapeutic discovery. Before his current role at Alentis, Vincent held a position as Principal Scientist at Galapagos, where he contributed to identifying biomarkers and therapeutic targets for fibrotic disorders. His academic background includes a PhD in Molecular Biology from the University of Rennes 1 (France) and a post-doctoral fellowship at Columbia University (New York, USA).
About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 antibodies and ADCs to modify and reverse the course of disease.
About Firalis Molecular Precision
Firalis Molecular Precision (FMP) is a fast-growing CRO & CDMO, providing advanced and tailored BioAnalytical Testing services to the Life Sciences sector, based in Huningue, France and in Cambridge, USA.
FMP’s team leverages its extensive scientific expertise and cutting-edge in-house platforms to provide a range of bioanalytical services, namely sample storage and management, multi-omics analysis, data analysis and interpretation, assay development and production – delivering high-quality data to support you along the entire drug development process.
FMP’s mission is to provide healthcare professionals, researchers and biopharmaceutical organizations with the solutions they need to make progress towards better patient care and a more personalized medicine.
About Firalis Molecular Precision's Spatial Omics Grant Program
The Grant Program with Vizgen was established to support transformative research projects that leverage spatial omics technologies to gain new insights into disease mechanisms. This innovative program aims to advance the understanding of complex biological systems by funding projects that utilize state-of-the-art molecular profiling tools.
Firalis Molecular Precision extends its congratulations to Vincent Anquetil and looks forward to the potential breakthroughs his research will bring to cancer immunotherapy.
Media Contact
Malak Ftouhi
Marketing & Communication Manager
+33 3 89 91 01 11
malak.ftouhi@firalis.com
Latest posts
Firalis Molecular Precision joins Janvier Group Biosciences 10.02.26 Huningue, France, February 10, 2026 – Firalis Molecular Precision, a company specialized in biomarkers and multi-omic analyses for...
International Day of Women and Girls in Science at FMP 11.02.26 Celebrating Women in STEM Huningue, France – International Day of Women and Girls in Science aims to recognize the essential role of...
The European Union is supporting the industrial development of Firalis Molecular Precision's new site in Huningue with funding for the EXOPROD project. 23.07.25 Huningue, France – Firalis...
Share this article on your socials